22nd Century Group Inc (NYSE:XXII) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Saturday. The firm currently has a $1.25 target price on the biotechnology company’s stock. Zacks Investment Research’s target price points to a potential downside of 10.07% from the stock’s current price.
According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “
Separately, Chardan Capital reiterated a “buy” rating and issued a $3.50 target price on shares of 22nd Century Group in a research note on Tuesday, March 7th.
22nd Century Group (NYSE:XXII) traded up 3.73% during mid-day trading on Friday, reaching $1.39. The company had a trading volume of 1,588,089 shares. The firm’s market capitalization is $126.07 million. 22nd Century Group has a 12-month low of $0.73 and a 12-month high of $1.71. The firm has a 50-day moving average price of $1.12 and a 200 day moving average price of $1.09.
WARNING: This article was reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The original version of this article can be accessed at https://www.com-unik.info/2017/04/21/22nd-century-group-inc-xxii-upgraded-at-zacks-investment-research-updated-updated.html.
An institutional investor recently raised its position in 22nd Century Group stock. National Asset Management Inc. raised its stake in shares of 22nd Century Group Inc (NYSE:XXII) by 82.8% during the third quarter, according to its most recent disclosure with the SEC. The firm owned 145,700 shares of the biotechnology company’s stock after buying an additional 66,000 shares during the period. National Asset Management Inc. owned about 0.16% of 22nd Century Group worth $197,000 as of its most recent filing with the SEC.
22nd Century Group Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about 22nd Century Group Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for 22nd Century Group Inc and related companies.